Cellebrite (NASDAQ: CLBT) CTO discloses 610,453-share stake including RSUs

Rhea-AI Filing Summary

Cellebrite DI Ltd. Chief Technology Officer Wade Christopher Michael has reported his initial ownership of 610,453 ordinary shares. This Form 3 filing is a disclosure of his existing stake rather than a new trade.

The total includes 31,593 ordinary shares represented by restricted share units granted on February 10, 2026. Of these RSUs, 7,905 are scheduled to vest on the first anniversary of the grant date, and 1,974 vest every three months thereafter through February 10, 2030. Each RSU converts into one ordinary share when it settles, tying part of his compensation directly to future company performance.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Wade Christopher Michael

(Last) (First) (Middle)

94 SHLOMO SHMELZER ROAD

(Street)

PETAH TIKVA 4970602

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Cellebrite DI Ltd. [ CLBT ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technology Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary shares, par value NIS 0.00001 ("Ordinary Shares")	610,453(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Includes 31,593 Ordinary Shares that are represented by restricted share units ("RSUs") that were granted on February 10, 2026 and vest as follows: 7,905 vest on the first anniversary of the grant date and 1,974 vest every three months thereafter through February 10, 2030. Each RSU represents a contingent right to receive one Ordinary Share of the Issuer upon settlement.

	/s/ Christopher Wade	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Cellebrite (CLBT) Form 3 filing by the CTO show?

The Form 3 shows CTO Wade Christopher Michael beneficially owns 610,453 ordinary shares of Cellebrite DI Ltd. This is an initial ownership report, not a record of recent buying or selling activity in the company’s stock.

How many Cellebrite (CLBT) shares are held through RSUs by the CTO?

The CTO’s reported holdings include 31,593 ordinary shares represented by restricted share units (RSUs). These RSUs convert into ordinary shares upon settlement, meaning part of his disclosed stake depends on future vesting rather than already-issued stock.

What is the vesting schedule of the Cellebrite (CLBT) RSUs reported?

The RSUs were granted on February 10, 2026. 7,905 RSUs vest on the first anniversary of the grant, and 1,974 RSUs vest every three months thereafter through February 10, 2030, gradually increasing the CTO’s settled share ownership over time.

Are the RSUs in the Cellebrite (CLBT) Form 3 a separate security?

Each RSU represents a contingent right to receive one ordinary share of Cellebrite DI Ltd. upon settlement. They are not ordinary shares until vested and settled, but are counted in the reported beneficial ownership because they are part of the CTO’s equity-based compensation.

Does the Cellebrite (CLBT) Form 3 indicate insider buying or selling?

No specific buy or sell transactions are identified in this Form 3. It primarily reports the CTO’s existing beneficial ownership of 610,453 ordinary shares, including shares tied to RSUs, rather than recording market trades or option exercises.